Tucson, Ariz. — Lightsense Technology, a leading developer of multispectral solutions to address significant problems in public health–from the opioid crisis to the pandemic, food safety and quality assurance in the pharmaceutical supply chain–today announces a new channel partnership to launch DrugDetect-M1 for organizations Law enforcement in relevant channels in the United States.

“We are very excited to partner with Lightsense Technology with an innovative illegal drug detection solution for law enforcement and, subsequently, to bring pathogen detection products to market in the future,” Robert DanesCEO of ICN Group. “DrugDetect-M1 is compelling evidence of the power of this new light-based detection technology. We are pleased to be part of their efforts.”

The DrugDetect platform provides a solution that is easy to operate and provides great sensitivity with high levels of accuracy at an affordable price. This platform could help tackle a difficult opioid epidemic by providing a new tool for law enforcement to see if a white powdery substance inside a thin plastic bag could pose a threat, helping them do their job efficiently and safely.

“We are pleased to collaborate with ICN Group to provide unique and valuable solutions to broader channels within the United States,” he said. Terry Scottheim, founder and CEO of Lightsense Technology. “This is the beginning of a new and ongoing path to transform our advanced research and development efforts into solutions into various channels, leading to greater access to our products, enhanced shareholder value, and better solutions to various problems in public health.”

About Lightsense
Lightsense has developed a groundbreaking multispectral technology platform, such as its patented Image Detection Spectroscopy (EPS), a radical new spectroscopic design, for the identification of chemical, molecular and pathogens. Their advanced designs for high-sensitivity miniature spectrophotometers also enable the use of new, lightweight, inexpensive portable devices to support solutions such as law enforcement organizations and others. These devices can address critical analytical and detection problems in a wide range of large vertical markets in “public health,” such as rapid detection of illicit drugs, rapid screening for viral/bacterial pathogens, and monitoring of bacterial pathogens in various parts of the food supply chain.

For more information, visit www.lightsensetechnology.com, or call 1-888-736-7349.

About ICN . Group
The ICN group of companies is a robust network of best-in-class practitioners working with vendors of IT, consumer electronics, mobile, security, communications, education, and emerging technology. ICN is a boutique firm specializing in channel consulting, research, market development, branding and global sales services. We are an experience-driven company that specializes primarily in the North American market and helps customers sell more effectively and through B2B, B2E and B2C channels. See https://theicngroup.com/